Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
Titel:
Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
Auteur:
Mok, T.S.K Wu, Y.-L. Kudaba, I. Kowalski, D.M. Cho, B.C. Turna, H.Z. de Castro Jr, G. Srimuninnimit, V. Laktionov, K.K. Bondarenko, I. Kubota, K. Caglevic, C. Karaszewska, B. Dang, T. Yin, L. Penrod, J. Lopes, G.